Moors & Cabot’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q2
Sell
-14
Closed -$3K 688
2020
Q1
$3K Buy
+14
New +$1.92K ﹤0.01% 586
2019
Q3
Sell
-1,600
Closed -$1K 684
2019
Q2
$1K Buy
+1,600
New +$188K ﹤0.01% 554
2016
Q4
Sell
-2,000
Closed -$3K 566
2016
Q3
$3K Buy
+2,000
New +$160K ﹤0.01% 544
2016
Q2
Sell
-2,000
Closed -$1K 535
2016
Q1
$1K Buy
+2,000
New +$151K ﹤0.01% 519

Other funds holding LLY

Moors & Cabot's LLY Position: Q1 2026 in Review

Moors & Cabot reduced its Eli Lilly (LLY) stake by 0.23% in Q1 2026, selling an estimated $53.7K and leaving 23,250 shares worth $21.4M. The position accounts for 0.92% of the portfolio, ranked #15.

Moors & Cabot first reported a position in LLY in Q1 2014 and has held it in 49 quarters since. The position peaked at $25M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Moors & Cabot held 23,250 shares of Eli Lilly worth $21.4M as of Q1 2026.
  • Moors & Cabot sold 53 Eli Lilly shares in Q1 2026, an estimated $53.7K.
  • Eli Lilly made up 0.92% of Moors & Cabot's portfolio in Q1 2026, its #15 holding.
  • Moors & Cabot first reported a position in Eli Lilly in Q1 2014 and has held it in 49 quarters since.
  • Moors & Cabot's Eli Lilly position peaked at $25M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Moors & Cabot's 13F filing for Q1 2026, filed 8 May 2026.